LGALS3 and prostate cancer: GAL1 has been shown to promote the prometastatic function of the glycocalyx (3), whereas GAL3 has been reported as a promoter of several kinds of cancer; data from prostate cancer are controversial (46); GAL3 is higher in benign prostatic hyperplasia and lower in adenocarcinoma compared to control patients (46, 47).